Liver Transplant Recipients Clinical Trial
Official title:
Immunomonitoring of Transplant Patients
The purpose of this study is to see what a lab test will show and if there is a way to predict which patients will be more likely to have rejection after receiving a liver transplant.
Status | Active, not recruiting |
Enrollment | 200 |
Est. completion date | November 2015 |
Est. primary completion date | November 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 17 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Received a liver Transplant Exclusion Criteria: - Received Multiple Organ Transplant |
Observational Model: Case-Only, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | Baylor University Medical Center | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
Baylor Research Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Identify signatures predictive of graft rejection or tolerance. | Analyze the pattern of gene expression in patients undergoing solid organ transplantation | 2 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00587418 -
L-arginine for Prevention of Kidney Damage in Liver Transplant Recipients
|
N/A | |
Completed |
NCT01889758 -
Pharmacokinetic Studies of Tacrolimus in Transplant Patients
|
Phase 4 | |
Completed |
NCT02482974 -
Conversion From Sirolimus to Everolimus in the Maintenance Treatment of Liver Transplant Recipients
|
N/A | |
Completed |
NCT02320422 -
Adult Liver Transplant Enhanced Care
|
N/A | |
Active, not recruiting |
NCT05077254 -
COVID Protection After Transplant-Immunosuppression Reduction
|
Phase 2 | |
Completed |
NCT00275639 -
The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver Transplant
|
Phase 4 | |
Completed |
NCT01672164 -
Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients
|
N/A | |
Completed |
NCT01638559 -
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
|
Phase 2 | |
Recruiting |
NCT06418893 -
Effect of TCI Propofol on Liver Transplant (TCI) Propofol on Intra-operative Usage of Vasopressors in Liver Transplant Recipients.
|
Phase 2/Phase 3 |